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Abstract: The association between a common PRSS1-PRSS2 haplotype and alcoholic chronic pancreatitis
(ACP), which was revealed by the first genome-wide association study of chronic pancreatitis
(CP), has been consistently replicated. However, the association with non-ACP (NACP) has been
controversial. Herein, we sought to clarify this basic issue by means of an allele-based meta-analysis
of currently available studies. We then used studies informative for genotype distribution to explore
the biological mechanisms underlying the association data and to test for gene-environment interaction
between the risk haplotype and alcohol consumption by means of a re-analysis. A literature search
was conducted to identify eligible studies. A meta-analysis was performed using the Review Manager
software. The association between the risk genotypes and NACP or ACP was tested for the best-fitting
genetic model. Gene-environment interaction was estimated by both case-only and multinomial
approaches. Five and eight studies were employed for the meta-analysis of ACP and NACP
findings, respectively. The risk allele was significantly associated with both ACP (pooled odds
ratio (OR) 1.67, 95% confidence interval (CI) 1.56–1.78; p < 0.00001) and NACP (pooled OR 1.28,
95% CI 1.17–1.40; p < 0.00001). Consistent with a dosage effect of the risk allele on PRSS1/PRSS2 mRNA
expression in human pancreatic tissue, both ACP and NACP association data were best explained
by an additive genetic model. Finally, the risk haplotype was found to interact synergistically with
alcohol consumption.
Keywords: chronic pancreatitis; gene-environment interaction; meta-analysis; PRSS1-PRSS2;
re-analysis; rs10273639
1. Introduction
Chronic pancreatitis (CP) is a chronic inflammatory process of the pancreas that leads to irreversible
morphological changes and progressive impairment of both exocrine and endocrine functions [1,2].
CP can be caused by genetic and/or environmental factors [3]. In the one extreme, rare gain-of-function
missense or copy number variants in the PRSS1 gene (encoding cationic trypsinogen; MIM# 276000)
can cause autosomal dominant hereditary pancreatitis [4,5]. In the other extreme, alcohol abuse is
the most frequent environmental factor causing CP worldwide [2,3].
Eight years ago, the first genome-wide association study of CP was published; a common
PRSS1-PRSS2 haplotype was reported to be associated with both alcoholic CP (ACP) and non-ACP
Genes 2020, 11, 1349; doi:10.3390/genes11111349 www.mdpi.com/journal/genes
Genes 2020, 11, 1349 2 of 16
(NACP) [6]. PRSS2 encodes anionic trypsinogen (MIM# 601564), the second major trypsinogen isoform
after cationic trypsinogen. This association has a strong biological basis: the risk (C) allele of the lead
single nucleotide polymorphism (SNP), rs10273639C/T, appeared to be associated with increased PRSS1
mRNA expression in pancreatic tissue in a dosage-dependent manner [6]. rs10273639C/T is in perfect
linkage disequilibrium with rs4726576C/A, which is located 204 bp upstream of the translation initiation
codon of the PRSS1 gene; the C allele of rs4726576C/A increased reporter gene expression as determined
by an in vitro promoter assay [7]. Uncontrolled trypsin activity is central to CP pathogenesis [8].
Another interesting finding from the Whitcomb study was that rs10273639C/T was associated with
a stronger genetic effect in ACP than in NACP, suggesting that the SNP-conferred risk was amplified
by alcohol consumption. Moreover, in a case-only analysis, the SNP seemed to interact with ACP [6].
In subsequent studies, the association of the common PRSS1-PRSS2 haplotype with ACP has been
consistently replicated. However, the association with NACP was equivocal, raising the possibility
that the common PRSS1-PRSS2 haplotype modifies CP risk only for ACP but not in NACP [9,10].
To explore this basic question and the underlying biological mechanisms, we firstly performed an
allele-based meta-analysis of the reported associations between the common PRSS1-PRSS2 haplotype
and ACP and NACP. We then used informative studies in terms of genotype distribution to perform
a new re-analysis with respect to (i) the fit of different genetic models to the association data
and (ii) the gene-environment interaction between the common PRSS1-PRSS2 haplotype and alcohol
consumption status in CP.
2. Materials and Methods
2.1. Literature Search and Inclusion Criteria
The literature search was performed by keyword search (PRSS1 and Pancreatitis) via PubMed
(as of 13 July 2020), which was complemented by the perusal of references citing the Whitcomb and/or
Derikx studies [6,9] via Google Scholar. Only studies that satisfied the following criteria were included
for meta-analysis: (i) published in a peer-reviewed journal; (ii) the common PRSS1-PRSS2 haplotype
was analysed in both ACP and/or NACP patients and controls; and (iii) the tagging SNP of interest
was in Hardy–Weinberg equilibrium in the controls.
2.2. Data Extraction
The protective alleles of the single nucleotide polymorphisms (SNPs) that tagged the common
PRSS1-PRSS2 haplotype have often been used for statistical analysis in previous publications.
To consider the genetic effects of both rare and common PRSS1 variants in the same framework,
herein, we used the risk alleles of the tagging SNPs for analysis. To this end, risk allele or genotype
distribution data in patients and controls were manually extracted from the included studies.
2.3. Statistical Analysis and Meta-Analysis with Respect to Risk Allele Frequencies in Patients and Controls
The assessment of the significance of the differences between the frequencies of the risk-tagging
SNPs in patients and controls in the context of each study was performed by means of χ2 tests in R [11].
A difference was regarded as being statistically significant when the p-value was ≤0.05. The sample
size for case-control association studies was estimated using the Online Sample Size Estimator [12].
Meta-analysis, heterogeneity and sensitivity analyses and forest plots were all performed using
the Review Manager 5.3 software [13]. Funnel plots were not performed owing to the small number of
eligible studies [13,14]. The Mantel–Haenszel fixed-effect or random-effect model was used to compute
the pooled odds ratio (OR) in the absence or presence of statistical heterogeneity. Heterogeneity was
considered to be significant when the p-value for the test of heterogeneity was <0.05 or I2 was 50%
or more [13,15]. The conduct and reporting of the meta-analysis were essentially in accordance with
the PRISMA guidelines [16]. This meta-analysis was not registered in PROSPERO [17], which does not
allow the registration of already complete studies.
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2.4. Evaluation of the Effect of rs10273639 on the Expression of PRSS1 and PRSS2 in Pancreatic Tissue
This analysis was performed using the Genotype-Tissue Expression (GTEx) dataset [18].
2.5. Re-Analysis for Association between the Common PRSS1-PRSS2 Haplotype and ACP/NACP Under
Different Genetic Models
Logistic regression models were fitted to examine the association between the risk genotypes
and NACP or ACP in the context of single population data (refer to Results). Four models were tested:
the genotypes were coded as either recessive, dominant, additive, or as each having an independent
effect (general model) [19]. We evaluated the Akaike information criterion (AIC) for each model
and tested the change in deviance of the recessive, dominant and additive models against the general
model. Pearson’s residuals were calculated to ensure the reasonability of the models fitted. All analyses
were carried out using the statistical analysis software R (version 3.6.1) [11].
2.6. Re-Analysis to Test for Interaction between the Common PRSS1-PRSS2 Haplotype and Alcohol
Consumption Status in CP
The studies included in this analysis were those for which we could ascertain individual-level
genotype data for ACP, NACP and healthy control individuals. We firstly performed case-only analyses
before combining results through meta-analysis in order to estimate a pooled OR for the interaction
term (also referred to as the synergy index SIM). This analysis was performed using the metagen
function from the meta R package [20].
In a second step, we applied the multinomial approach to test for gene-environment interactions
as proposed by Kazma and colleagues [21]. ACP and NACP patients were compared using the control
individuals as a common baseline through a multinomial logistic regression model (multinom function
from the nnet R package) [22]. Since we combined data from different sources, the multinomial
model included co-variables indicating the country- and study-origin of the data; and we applied
the additive genetic model for the genetic effects. This method of investigating the gene-environment
interaction is equivalent to the case-only approach [23] and tests the interaction on a multiplicative
scale [24]. However, unlike the case-only approach, the multinomial model allows us to also include a
control group and hence to simultaneously estimate the genetic effects and test for the presence of an
interaction term, thereby giving a more complete description.
3. Results
3.1. Included Studies for Meta-Analysis
The keyword search (PRSS1 and Pancreatitis) via PubMed resulted in 173 entries starting from
the pioneering Whitcomb study [6]. Of these, 15 publications were identified to report original data
on the frequency of the common PRSS1-PRSS2 haplotype in both pancreatitis patients and controls.
Two studies that analysed patients with a known non-alcohol-related external factor [25,26] and three
studies that analysed only patients with acute pancreatitis [27–29] were immediately excluded from
further consideration. Two additional reports that analysed CP patients were also excluded: one [30]
because of a significant overlap of patients with a previous study [9] and the other due to its small
sample size (i.e., only 85 CP cases and 78 controls were successfully genotyped) and lack of information
on the numbers of CP subtypes among the analysed patients [31]. The remaining eight studies were
included in our meta-analysis; five of these reported data on both ACP and NACP [6,9,10,32,33],
whereas the other three reported data only for NACP [34–36]. The search and selection processes of
the included studies are outlined in Figure 1. In all included studies, the tagging SNP of interest was
either described in the original publication or verified here to be in Hardy–Weinberg equilibrium in
the controls. Additionally, all included studies were evaluated to have a Newcastle–Ottawa Scale (NOS)
score [37] of ≥7. Finally, the perusal of references citing the Whitcomb study [6] and/or the Derikx
study [9] via Google Scholar did not identify additional eligible studies in peer-reviewed journals.
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Table 1. Basic characteristics of the included studies and corresponding risk allele frequencies for the common PRSS1-PRSS2 haplotype-tagging SNPs in patients
and controls.
Study Study Population(s) Risk Allele of theTagging SNP
Number of
Patients/Controls
Allele Frequency
in Patients
Allele Frequency
in Controls OR (95% CI) p Value (χ
2 Test)
ACP
Whitcomb et al. [6]
Mainly Americans with
European ancestry and a
small number of German
and British subjects
rs10273639[C] 447 a/8029 69.6% (622/894) 57.6%(9249/16,058) 1.68 (1.45–1.95) 2.03 × 10
−12
Derikx et al. [9] European (from 9 countries) rs10273639[C] 1854/5065 69.0% (2560/3708) 57.6%(5835/10,130) 1.64 (1.52–1.78) 2.20 × 10
−16
Masamune et al. [32] Japanese rs10273639[C] 272/480 32.5% (177/544) 22.2% (213/960) 1.69 (1.34–2.14) 1.43 × 10−5
Giri et al. [33] Indian rs2855983[G] 85/1288 48.8% (83/170) 34.0% (876/2576) 1.85 (1.36–2.53) 0.00012
Hegyi et al. [10] Hungarian rs6666[C] 120/296 70.0% (168/240) 57.3% (339/592) 1.74 (1.26–2.40) 0.00086
NACP
Whitcomb et al. [6]
Mainly Americans with
European ancestry and a
small number of German
and British subjects
rs10273639[C] 1129 b/8029 63.4% (1431/2258)
57.6%
(9249/16,058) 1.27 (1.16–1.40) 2.10 × 10
−7
Derikx et al. [9] European (from threecountries) rs10273639[C] 1192/4323 59.6% (1421/2384) 57.6% (4981/8646) 1.09 (0.99–1.19) 0.085
Masamune et al. [32] Japanese rs10273639[C] 197/480 30.5% (120/394) 22.2% (213/960) 1.54 (1.18–2.00) 0.0017
Avanthi et al. [34] Indian rs10273639[C] 96/156 30.7% (59/192) 28.9% (90/312) 1.09 (0.74–1.62) 0.73
Giri et al. [33] Indian rs2855983[G] 434/1288 42.0% (364/868) 34.0% (876/2576) 1.40 (1.20–1.64) 3.07 × 10−5
Paliwal et al. [35] Indian rs10273639[C] 551/801 33.8% (372/1102) 26.9% (431/1602) 1.38 (1.17–1.64) 0.00015
Campa et al. [36] European (from 8 countries) rs10273639[C] 345/4580 64.4% (444/690) 57.8% (5292/9160) 1.32 (1.12–1.55) 0.00085
Hegyi et al. [10] Hungarian rs6666[C] 103/296 63.1% (130/206) 57.3% (339/592) 1.28 (0.92–1.77) 0.17
a Including 113 patients with recurrent acute pancreatitis. b Including 462 patients with recurrent acute pancreatitis. Abbreviations: ACP, alcoholic chronic pancreatitis; CI, confidence
interval; NACP, non-alcoholic chronic pancreatitis; OR, odds ratio; SNP, single nucleotide polymorphism.
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3.2. Allele-Based Meta-Analysis Confirmed an Association of the Common PRSS1-PRSS2 Haplotype with Both
ACP and NACP
Although the frequencies of the risk-tagging alleles differ significantly (from 22% to 58%)
between the American (primarily of European ancestry), European, Japanese, Indian and Hungarian
control populations studied, all five ACP studies found a statistically significant association between
the common PRSS1-PRSS2 haplotype and ACP with remarkably comparable ORs (i.e., 1.64 to 1.85;
Table 1). Application of the test for heterogeneity confirmed that the five studies were homogeneous
(χ2 = 0.68, p = 0.95; I2 = 0%). The pooled OR (under a fixed effect model) was 1.67 (95% CI 1.56–1.78;
p < 0.00001) (Figure 2).Genes 2 20, 1 , x OR PEER REVIEW 7 of 17 
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Figure 2. Results of the allele-based meta-analysis of the association between the common PRSS1-PRSS2
haplotype and ACP or NACP, and the corresponding forest plots. Total events in patients and controls:
number of risk alleles/number of total alleles. See Table 1 for the risk allele distribution data, OR
(95% CI) and p values in the context of each individual study. Abbreviations: ACP, alcoholic chronic
pancreatitis; CI, confidence interval; NACP, non-alcoholic chronic pancreatitis; OR, odds ratio.
Of the eight NACP studies, five found a statistically significant association with NACP,
whereas the other three did not (Table 1). The test for heterogeneity revealed significant heterogeneity
across the studies (χ2 = 15.81, p = 0.03; I2 = 56%). Sensitivity analysis identified the large European
study [9] to be the source of the heterogeneity. Using a random-effect model, the common PRSS1-PRSS2
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haplotype showed significant association with NACP: the pooled OR was 1.28 (95% CI 1.17–1.40;
p < 0.00001) (Figure 2).
The three studies that failed to show a significant association with NACP nevertheless, all yielded
ORs > 1 (Table 1). Notably, the frequency of the tagging rs6666(C) allele among the Hungarian
NACP patients was nearly 6% higher than in controls (i.e., 63.1% vs. 57.3%), raising the possibility
that the absence of an association (p = 0.17) in the corresponding study [10] might have been due
to the relatively small sample size (only 103 patients and 296 controls were examined). Assuming
(i) the frequencies of the rs6666(C) allele in the Hungarian NACP patients and controls were 63%
and 57%, respectively and (ii) a 1:2 ratio of cases to controls, at least 784 patients and 1568 controls
would have been required to achieve significance at the 5% level with 80% power.
As for the large European study [9], the risk allele frequency in the NACP patients was 2% higher
than in the controls, yielding a p-value of 0.085 (Table 1). This large study used three NACP cohorts, viz.
German, French and Dutch. The German cohort was the largest and showed a statistically significant
association with NACP (OR = 1.21, p = 0.0027; Table 2).
Table 2. Comparison of the rs10273639(C) allele frequencies in the NACP patients and controls in the
context of each population studied by Derikx et al. [9].
Population Number ofPatients/Controls
Allele
Frequency in
Patients
Allele
Frequency in
Controls
OR (95% CI) p Value(χ2 Test)
German 690/2825 62.97%(869/1380)
58.50%
(3305/5650)
1.21
(1.07–1.36) 0.0027
French 415/1064 54.10%(449/830)
54.61%
(1162/2128)
0.98
(0.83–1.15) 0.83
Dutch 87/434 59.20%(103/174)
59.22%
(514/868)
1.00
(0.72–1.39) 1.00
Abbreviations: OR, odds ratio; CI, confidence interval; NACP, non-alcoholic chronic pancreatitis.
The third study that failed to achieve a significant association [34] was the smallest of the three
Indian studies (Table 1).
3.3. The Risk Allele Number is Positively Correlated with the Pancreatic PRSS2 mRNA Expression Level
We evaluated whether the risk (C) allele of rs10273639C/T is associated with increased trypsinogen
gene expression in the pancreas in the GTEx dataset. No significant expression quantitative trait
loci (eQTLs) for PRSS1 in the pancreas are currently available in GTEx. However, the genotypes of
rs10273639 affected PRSS2 mRNA expression in the pancreas in a dosage-dependent manner (Figure 3).
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3.4. The Additive Genetic Model Best Fits the Associations of the Common PRSS1-PRSS2 Haplotype with
NACP and ACP
The positive correlation between the risk allele number of rs10273639 and in vivo PRSS1 and PRSS2
mRNA expression implies that an additive genetic model would best explain the association data.
To test this postulate, we firstly examined the three possible genetic models (i.e., dominant, recessive
and additive), in the context of three NACP studies informative for genotype distribution, each from
a single population (i.e., the only Japanese study [32], the Paliwal study that analysed the largest
number of Indian patients [35], and the German cohort (the largest of the European cohorts) studied
by Derikx et al. [9]). A general model with an independent effect of each genotype was also fitted
to aid the evaluation of the three models of interest. The distribution of the rs10273639 genotypes
showed significant differences between patients and controls under all three genetic models (Table 3).
Pearson’s residuals (which should not greatly exceed a value of two) were calculated to establish that
all models had provided a reasonable description of the data. By evaluating the Akaike information
criterion (AIC), we observed that the best fitting model was invariably the additive model as a lower
AIC represents a better model fit. On examining the general models, we observed that the coefficients
for the CC genotype were very close to twice the coefficients of the CT genotype (i.e., 0.39 vs. 0.25
in the German data; 0.87 vs. 0.45 in the Japanese data; and 0.59 vs. 0.34 in the Indian data). This is
indicative of an additive dose-dependent relationship between the genotypes and the risk of CP.
Further, we performed analyses of variance (ANOVA) of the recessive, dominant and additive models
against the general model. This showed that only the recessive model provided a worse description of
the data compared to the general model (p values below 0.05) (Table 3).
We also examined the three possible genetic models in the context of ACP studies. Of the five
included ACP studies (Table 1), four used only healthy subjects as controls [6,10,32,33]. The Derikx
study [9] additionally used German subjects with alcohol dependence (AD) and alcohol-associated
liver cirrhosis (ALC) as controls. We, therefore, limited this analysis exclusively to the German data
and tested the fit of the three genetic models to ACP association in the context of three control datasets.
Again, the additive model provided the best fit to each dataset as evaluated by the AIC and by
Anova tests against the general model. Pearson’s residuals did not indicate that the models fitted
were unreasonable and in each dataset tested, a clearly significant correlation between genotypes of
rs10273639 and the case/control status was observed as evidenced by the significant ORs (Table 4).
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Table 3. Test of the fit of different genetic models to the gene association data in three NACP cohorts.
NACP Cohort Genotypes of rs10273639 Dominant Model Recessive Model Additive Model General Model
CC CT TT CC CT TT CC CT TT CC CT TT CC CT TT
Pearson’s Residuals Pearson’s Residuals Pearson’s Residuals Pearson’s Residuals
German a
Patients 274 321 95 1.97 2.31 1.89 2.10 1.88 2.03 2.26 1.90 2.04 2.31
Controls 985 1335 505 −0.51 −0.43 −0.52 −0.48 −0.53 −0.47 −0.44 −0.53 −0.49 −0.43
Japanese b
Patients 17 86 94 1.36 1.75 1.14 1.60 1.12 1.41 1.75 1.14 1.40 1.75
Controls 22 169 289 −0.73 −0.57 −0.88 −0.63 −0.89 −0.71 −0.57 −0.90 −0.71 −0.57
Indian c
Patients 68 236 247 1.09 1.33 0.99 1.23 0.97 1.13 1.32 0.99 1.12 1.33
Controls 67 297 437 −0.91 −0.75 −1.01 −0.81 −1.03 −0.88 −0.76 −1.01 −0.89 −0.75
OR (95% CI); p
value
German 1.36 (1.08–1.73); 0.010 1.23 (1.04–1.46); 0.017 1.20 (1.07–1.36); 0.0027 -
Japanese 1.66 (1.19–2.32); 0.0029 1.97 (1.02–3.79); 0.040 1.55 (1.19–2.03); 0.0013 -
Indian 1.48 (1.19–1.84); 0.00044 1.54 (1.08–2.20); 0.017 1.36 (1.16–1.61); 0.00020 -
AIC
German 3478.59 3479.89 3476.41 3478.101
Japanese 811.68 816.59 810.28 812.27
Indian 1819.40 1826.12 1817.92 1819.79
ANOVA test
against General
model (p value)
German 0.115 0.052 0.581 -
Japanese 0.235 0.0120 0.945 -
Indian 0.205 0.00389 0.710 -
a Using NACP data from Derikx et al. [9]. b Using NACP data from Masamune et al. [32]. c Using NACP data from Paliwal et al. [35]. Abbreviations: AIC, Akaike information criterion;
CI, confidence interval; OR, odds ratio; NACP, non-alcoholic chronic pancreatitis.
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Table 4. Test of the fit of different genetic models to three German ACP association datasets *.
Association
Genotypes of rs10273639 Dominant Model Recessive Model Additive Model General Model
CC CT TT CC CT TT CC CT TT CC CT TT CC CT TT
Pearson’s Residuals Pearson’s Residuals Pearson’s Residuals Pearson’s Residuals
Dataset 1
ACP patients 433 358 73 1.71 2.63 1.51 2.07 1.50 1.96 2.56 1.51 1.93 2.63
Healthy controls 985 1335 505 −0.58 −0.38 −0.66 −0.48 −0.67 −0.51 −0.39 −.66 −0.52 −0.38
Dataset 2
ACP patients 433 358 73 0.97 1.43 0.80 1.19 0.81 1.10 1.50 0.81 1.13 1.43
AD controls 281 456 150 −1.04 −0.70 −1.24 −0.84 −1.23 −0.90 −0.67 −1.24 −0.89 −0.70
Dataset 3
ACP patients 433 358 73 0.81 1.29 0.72 0.98 0.71 0.93 1.22 0.72 0.91 1.29
ALC controls 226 296 121 −1.23 −0.78 −1.38 −1.02 −1.41 −1.07 −0.82 −1.38 −1.10 −0.78
OR (95% CI); p
value
Dataset 1 2.36 (1.83–3.08); 7.5 × 10−11 1.87 (1.61–2.19); 1.2 × 10−15 1.70 (1.52–1.92); < 2 × 10−16
Dataset 2 2.21 (1.64–2.98); 1.8 × 10−7 2.17 (1.79–2.63); 6.4 × 10−15 1.83 (1.59–2.13); 2.3 × 10−16
Dataset 3 2.51 (1.85–3.44); 6.3 × 10−9 1.85 (1.50–2.29); 9.1× 10−9 1.72 (1.48–2.01); 2.6 × 10−12
AIC
Dataset 1 3970.12 3956.1 3934.80 3936.334
Dataset 2 2402.35 2369.12 2360.65 2361.82
Dataset 3 2025.64 2026.78 2010.17 2011.12
ANOVA against
General Model
(p-value)
Dataset 1 2.20 × 10−9 3.08 × 10−6 0.496
Dataset 2 6.89 × 10−11 0.0023 0.362
Dataset 3 4.8 × 10−5 2.6 × 10−5 0.307
* Genotype data from Derikx et al. [9]. Abbreviations: ACP, alcoholic chronic pancreatitis; AD, alcohol dependence; AIC, Akaike information criterion; ALC, alcohol-associated liver
cirrhosis; CI, confidence interval; OR, odds ratio.
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3.5. A Synergistic Interaction is Evident between the Common PRSS1-PRSS2 Haplotype and Alcohol
Consumption Status
Using data from ACP and NACP patients from Germany, France, Netherlands, Japan and Hungary
(Table 5), we first performed case-only re-analyses of each dataset to estimate the OR of the interaction
between alcohol-consumption and copies of the PRSS1/PRSS2 haplotype. Following the evaluation of
different genetic models in NACP and ACP patients, we selected the best-performing additive genetic
model for this re-analysis. Subsequently, we performed a meta-analysis of these new results in order
to calculate a pooled estimate for the interaction term and to assess the heterogeneity of the studies.
Application of the test for heterogeneity confirmed that the five studies were homogeneous (χ2 = 4.78,
p = 0.31; I2 = 16.4%). The pooled OR (under a fixed effect model) of the interaction (or synergy index of
multiplicity, SIM) was 1.41 (95% CI 1.26–1.58; p = 2.80 × 10−9). That the OR is significantly greater than
one indicates that the interaction effects between alcohol exposure and the haplotype are more than
multiplicative (synergistic effect).
Table 5. Estimation of gene-environment interaction between the common PRSS1-PRSS2 haplotype
and alcohol consumption using a case-only analysis.
Population a OR (95% CI) b p Value
German 1.43 (1.23–1.66) 4.14 × 10−6
French 1.54 (1.11–2.15) 0.010
Dutch 1.84 (1.25–2.73) 0.0022
Japanese 1.11 (0.83–1.49) 0.48
Hungarian 1.34 (0.91–1.98) 0.14
Pooled (fixed effect model) 1.41 (1.26–1.58) 2.80 × 10−9
a Original German, French and Dutch data used for analysis were from Derikx et al. [9].
Original Japanese and Hungarian data used for analysis were from Masamune et al. [32] and Hegyi
et al. [10], respectively. b For the effect of the risk genotypes in the alcoholic chronic pancreatitis
group against the non-alcoholic chronic pancreatitis group, equivalent to an estimate of the
multiplicative-scale interaction term (or synergy index) between PRSS1/PRSS2 and alcohol
consumption. Abbreviations: CI, confidence interval; OR, odds ratio.
To fully characterise the importance of the interaction, we fitted a multinomial logistic regression
model to estimate, within a single framework, the risks associated with the PRSS1-PRSS2 haplotype
in both ACP and NACP cases (Table 6). For this analysis, control groups were required from each
population. It should be noted that the purpose of the model is to compare the ACP and NACP against
a common baseline, and hence no assumption is made about alcohol consumption in the control groups.
The OR for the PRSS1/PRSS2 haplotype was 1.16 (95% CI 1.07–1.26) in the NACP patients and increased
to 1.69 (95% CI 1.54–1.84) in the ACP patients. The difference between these two ORs was statistically
significant, as evidenced by the non-overlapping confidence intervals, again signalling the presence of
an interaction between the genetic-effect of the haplotype and alcohol consumption. This model allows
for a succinct demonstration that alcohol consumption significantly increases the risk associated with
the presence of copies of the haplotype on a multiplicative scale across the five populations.
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Table 6. Test of gene-environment interaction between the common PRSS1-PRSS2 haplotype and alcohol
consumption using a multinomial logistic regression model.
Groups Population a
Genotypes of the Common
Haplotype b OR (95% CI) c
CC CT TT
Controls German 985 1335 505
French 316 530 218
Dutch 146 222 66
Japanese 22 169 289
Hungarian 98 143 55
NACP German 274 321 95
1.16 (1.07–1.26)
French 130 189 96
Dutch 28 47 12
Japanese 17 86 94
Hungarian 44 42 17
ACP German 433 358 73
1.69 (1.54–1.84)
French 36 45 9
Dutch 115 102 15
Japanese 23 131 118
Hungarian 59 50 11
a Original German, French and Dutch data used for analysis were from Derikx et al. [9]. Original Japanese
and Hungarian data used for analysis were from Masamune et al. [32] and Hegyi et al. [10], respectively.
b Genotypes for the German, French, Dutch and Japanese cohorts refer to rs102373639 whilst those for the Hungarian
cohort refer to rs6666. c For the effect of the risk genotypes in the ACP or NACP group against the control group.
4. Discussion
We first performed an allele-based meta-analysis of the currently available studies of the association
between the common PRSS1-PRSS2 haplotype and ACP and NACP, demonstrating a significant
association in both contexts. Possible causes underlying the previously contentious NACP findings
included small sample size, ethnic and population differences in genetic predisposition to CP,
and differences in patient selection. For example, using only German samples, Derikx and colleagues
observed a trend towards higher genetic effect sizes in patient groups characterised by a later age of
disease onset [9], a possible explanation for the lack of a significant association in the French cohort
(see Table 2). More specifically, a significant association was found in the German patients whose age of
disease onset was ≥20 years but not in those whose age of disease onset was 10–19 years or <10 years;
the age of disease onset was invariably <20 years in all French patients. Additionally, it should be
noted that PRSS1-PRSS2 rs10273639 was included in a recent meta-analysis, in which ACP and NACP
were analysed together [38].
Having confirmed an association of the common PRSS1-PRSS2 haplotype with NACP, we further
explored the underlying biological basis of this association from two complementary standpoints.
As mentioned earlier, the risk (C) allele of rs10273639C/T has been found to be positively associated
with PRSS1 mRNA expression in pancreatic tissue. More specifically, PRSS1 expression levels were
highest in rs10273639(C) homozygotes, intermediate in heterozygotes and lowest in rs10273639(T)
homozygotes [6]. However, the number of pancreatic tissue samples subjected to quantitative PRSS1
mRNA expression analysis was limited. We, therefore, evaluated the effect of rs10273639 genotypes
on pancreatic trypsinogen gene expression using the GTEx dataset and found the level of PRSS2
mRNA expression to correlate directly with the dosage of the risk (C) allele of rs10273639. A role
for PRSS2 in CP is supported by four lines of evidence. Firstly, a loss-of-function PRSS2 variant is
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known to be protective against CP [39]. Secondly, CP-causing or predisposing trypsinogen copy number
variants involve both PRSS1 and PRSS2 [5,40,41]. Thirdly, the CTRB1-CTRB2 inversion increases CP
risk by influencing protective PRSS2 degradation [30]. Finally, transgenic expression of human PRSS2
exacerbates pancreatitis in mice [42]. A dosage effect of the risk allele on PRSS1/PRSS2 expression in
the pancreas implies that the additive gene model represents the best fit to explain the disease association
data. Thus, the second approach we adopted was to test this hypothesis by a series of statistical analyses.
We demonstrated that the additive genetic model provided the best fit in both the ACP and NACP
contexts and the genetic effect of the rs10273639 CC genotype was approximately double that of the CT
genotype. Taken together, these findings provide new insights into the pivotal role of increased trypsin
in the aetiology of CP as well as the genotype-phenotype relationship in ACP/NACP.
Alcohol is an established environmental risk factor for CP [3]. However, only 3–5% of heavy
drinkers develop the disease [43], suggesting the involvement of additional genetic or environmental
factors in the causation of ACP. A higher OR for the common PRSS1-PRSS2 risk allele associated
with ACP than with NACP suggests a gene-environment interaction between the common haplotype
and alcohol consumption in CP. By comparing allele distributions at rs10273639 between 447 ACP
patients and 1129 NACP patients, Whitcomb and colleagues [6] suggested the existence of an interaction
between the PRSS1-PRSS2 haplotype and alcohol consumption although they did not attempt to
quantify it. Herein, by fitting a similar but more sophisticated model, and by combining inference
from data of several studies, we confirm that there is indeed a synergistic interaction between
the PRSS1-PRSS2 haplotype and alcohol consumption status, i.e., the risk associated with the presence
of the PRSS1-PRSS2 haplotype and exposure to alcohol was significantly greater than the product of
the risks associated with each factor singly. Our results are in accordance with those of Whitcomb
and colleagues but here, by first determining the correct genetic model (additive), and second by
applying multinomial logistic regression, a complete characterisation of the aetiology of CP regarding
the PRSS1-PRSS2 haplotype and alcohol consumption was obtained. These findings have important
implications for risk assessment and disease prevention in the age of precision medicine and should
also stimulate new studies designed to establish a general framework for understanding gene-alcohol
interactions in CP.
This study has several limitations. For example, we could not exclude publication bias in terms of
some of the included studies. We did not perform funnel plots to assess this possibility following advice
that such a test should be used only when there are at least ten eligible studies; otherwise, the power
of the test would have been too low to distinguish a chance effect from genuine asymmetry [13,14].
Despite lacking detailed records of individual alcohol consumption levels, we have studied the role
of alcohol by comparing ACP and NACP cohorts. We can be confident that these two groups will
have experienced quite different levels of alcohol consumption, and hence the methods applied here
are appropriate for detecting and describing a gene-environment interaction. More detailed data
regarding the environmental exposure variable could enable more precision in the characterisation
of the interaction. Moreover, there exist some differences between different cohorts in terms of ACP
and NACP definitions. For example, ACP was diagnosed in patients who had consumed at least
80 g ethanol per day in men or 60 g per day for women, for at least two years in two studies [9,32]
but for at least five years in one study [33], whereas no details on the amount or timespan of alcohol
consumption were provided in the remaining two studies [6,10]. Furthermore, none of the included
studies employed sex- and age-matched controls. However, we consider it unlikely that either of
the abovementioned limitations would affect the main conclusions drawn owing to the mechanistic
evidence underpinning the association data.
5. Conclusions
In conclusion, the results of our allele-based meta-analysis demonstrated a significant association
of the common PRSS1-PRSS2 haplotype with both ACP and NACP. In addition, we have provided
new information that sheds light on the pivotal role of uncontrolled trypsin in CP. Finally, we have
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refined the gene-environment interaction between the common PRSS1-PRSS2 haplotype and alcohol
consumption status in the aetiology of CP. These findings help to improve our understanding of
the complex aetiology of CP and strengthen the notion that common risk factors [6,30,44] should
be considered for risk assessment in the clinical setting. Acute pancreatitis patients carrying
the common PRSS1-PRSS2 haplotype should consider greatly reducing their alcohol consumption or
abstaining altogether.
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